Next-Generation Sequencing in Clinical Practice: Is It a Cost-Saving Alternative to a Single-Gene Testing Approach?
Giancarlo PruneriFilippo De BraudAnna SapinoMassimo AgliettaAndrea VecchioneRaffaele GiustiCaterina MarchiòStefania ScarpinoAnna BaggiGiuseppe BonettiJean Marie FranziniMarco VolpeClaudio JommiPublished in: PharmacoEconomics - open (2021)
An NGS-based approach may be less costly than an SGT-based approach; also, generated savings increase with the number of patients and different molecular alterations tested.